PTP4A2 and acute myeloid leukemia: In contrast, and consistent with the extended median survival, the prevalence of AML phenotypes was significantly reduced in WT, PRL2-KO, and PRL2-KO;PTEN HET groups, with only ~40% of the PRL2-KO;PTEN HET mice exhibiting a severe AML phenotype at 60 weeks.